Myasthenia gravis and related disorders: Pathology and molecular pathogenesis
- PMID: 25486268
- DOI: 10.1016/j.bbadis.2014.11.022
Myasthenia gravis and related disorders: Pathology and molecular pathogenesis
Abstract
Disorders affecting the presynaptic, synaptic, and postsynaptic portions of the neuromuscular junction arise from various mechanisms in children and adults, including acquired autoimmune or toxic processes as well as genetic mutations. Disorders include autoimmune myasthenia gravis associated with acetylcholine receptor, muscle specific kinase or Lrp4 antibodies, Lambert-Eaton myasthenic syndrome, nerve terminal hyperexcitability syndromes, Guillain Barré syndrome, botulism, organophosphate poisoning and a number of congenital myasthenic syndromes. This review focuses on the various molecular and pathophysiological mechanisms of these disorders, characterization of which has been crucial to the development of treatment strategies specific for each pathogenic mechanism. In the future, further understanding of the underlying processes may lead to more effective and targeted therapies of these disorders. This article is part of a Special Issue entitled: Neuromuscular Diseases: Pathology and Molecular Pathogenesis.
Keywords: Botulism; Congenital myasthenic syndrome; Lambert–Eaton myasthenic syndrome; Myasthenia gravis; Neuromuscular junction; Organophosphate poisoning.
Copyright © 2014 Elsevier B.V. All rights reserved.
Similar articles
-
Myasthenia and related disorders of the neuromuscular junction.J Neurol Neurosurg Psychiatry. 2010 Aug;81(8):850-7. doi: 10.1136/jnnp.2008.169367. Epub 2010 Jun 14. J Neurol Neurosurg Psychiatry. 2010. PMID: 20547629 Review.
-
Pathogenic Mechanisms and Clinical Correlations in Autoimmune Myasthenic Syndromes.Semin Neurol. 2018 Jun;38(3):344-354. doi: 10.1055/s-0038-1660500. Epub 2018 Jul 16. Semin Neurol. 2018. PMID: 30011414 Review.
-
Autoimmune disorders of neuromuscular transmission.Semin Neurol. 2008 Apr;28(2):212-27. doi: 10.1055/s-2008-1062260. Semin Neurol. 2008. PMID: 18351523 Review.
-
[Immunologic aspects of disorders of neuromuscular transmission. 2. Experimental autoimmune myasthenia gravis and the Lambert-Eaton myasthenic syndrome].Lijec Vjesn. 1994 May-Jun;116(5-6):158-61. Lijec Vjesn. 1994. PMID: 7968205 Croatian.
-
Clinical aspects of myasthenia explained.Autoimmunity. 2010 Aug;43(5-6):344-52. doi: 10.3109/08916931003602130. Autoimmunity. 2010. PMID: 20380587 Review.
Cited by
-
The potential role of cell surface complement regulators and circulating CD4+ CD25+ T-cells in the development of autoimmune myasthenia gravis.Electron Physician. 2016 Jan 15;8(1):1718-26. doi: 10.19082/1718. eCollection 2016 Jan. Electron Physician. 2016. PMID: 26955441 Free PMC article.
-
A novel thymoma-associated autoimmune disease: Anti-PIT-1 antibody syndrome.Sci Rep. 2017 Feb 20;7:43060. doi: 10.1038/srep43060. Sci Rep. 2017. PMID: 28216655 Free PMC article.
-
Time to response with ravulizumab, a long-acting terminal complement inhibitor, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis.Eur J Neurol. 2024 Dec;31(12):e16490. doi: 10.1111/ene.16490. Epub 2024 Oct 7. Eur J Neurol. 2024. PMID: 39373062 Free PMC article. Clinical Trial.
-
Two-decade battle with myasthenia gravis: A breakthrough case report on the long-term success with eculizumab and ravulizumab treatment.Clin Case Rep. 2024 Nov 4;12(11):e9547. doi: 10.1002/ccr3.9547. eCollection 2024 Nov. Clin Case Rep. 2024. PMID: 39502126 Free PMC article.
-
Sterol derivative binding to the orthosteric site causes conformational changes in an invertebrate Cys-loop receptor.Elife. 2023 Jul 3;12:e86029. doi: 10.7554/eLife.86029. Elife. 2023. PMID: 37395731 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous